Cardiovascular risks with prostate cancer hormonal treatment: rationale for a department of oncocardiology

• Published in: Cancer radiothérapie Vol. 20; no. 5; pp. 405 - 410
• Main Authors: Latorzeff, I, Ploussard, G, Guillotreau, J, Jonca, F, Labarthe, P, Rollin, G, Beauval, J-B, Pathak, A
• Format: Journal Article
• Language: French
• Published: France 01.07.2016
• Subjects: Androgen Antagonists - adverse effects; Cardiologists; Cardiology; Cardiotoxicity - etiology; Humans; Male; Medical Oncology; Oncologists; Patient Care Team; Prostatic Neoplasms - therapy; Risk Assessment; Risque cardiovasculaire; Cancer de la prostate; Cardiovascular risk; Hormonothérapie; Hormonal treatment; Prostate cancer; Unit of oncocardiology; Unité oncocardiologie
• ISSN: 1769-6658
• DOI: 10.1016/j.canrad.2016.02.015

Prostate cancer, the most frequent cancer in man, is an adenocarcinoma sensible to chemical castration in more than 80% of cases due to its hormonal dependency. Androgen deprivation is the treatment for advanced cancer and can be associated with radiotherapy locally or in locally advanced situations. Multidisciplinary therapeutic choice depends on patient age and co-morbidities and clinical stage. The impact of hormonal treatment confers varied side effects and cardiovascular effects are now better known. Responsible mechanisms of this cardiotoxicity are at the same time direct but also indirect by metabolic thermogenic effects. Analysis of these clinical or biological effects, their correlations to the used type of hormonal treatment and the possible precautions of prescription will be detailed in this analysis of the literature. The collaboration of the oncologist or the urologist with the cardiologist becomes necessary and the existence of a unit of oncocardiology could improve the evaluation of the risk-benefit balance and the tolerance of the treatment.